Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines
Authors:
Open Access
- 1 June 2024
- journal article
- research article
- Published by International Union Against Tuberculosis and Lung Disease in IJTLD OPEN
- Vol. 1 (6) , 242-249
Abstract
SUMMARY: BACKGROUND: In 2022, the WHO announced that the 6-month BPaL/M regimen should be used for drug-resistant TB (DR-TB). We estimate the patient and provider costs of BPaL compared to current standard-of-care treatment in the Philippines. METHODS: Patients on BPaL under operational research, or 9–11-month standard short oral regimen (SSOR) and 18–21-month standard long oral regimen (SLOR) under programmatic conditions were interviewed using the WHO cross-sectional TB patient cost tool. Provider costs were assessed through a bottom-up and top-down costing analysis. RESULTS: Total patient costs per treatment episode were lowest with BPaL (USD518.0) and increased with use of SSOR (USD825.8) and SLOR (USD1,023.0). Total provider costs per successful treatment were lowest with BPaL (USD1,994.5) and increased with SSOR (USD3,121.5) and SLOR (USD10,032.4). Compared to SSOR, BPaL treatment was cost-effective at even the lowest willingness to pay threshold. As expected, SLOR was the costliest and least effective regimen. CONCLUSIONS: Costs incurred by patients on BPaL were 37% (95% CI 22–56) less than SSOR and 50% (95% CI 32–68) less than SLOR, while providers could save 36% (95% CI 21–56) to 80% (95% CI 64–93) per successful treatment, respectively. The study shows that treatment of DR-TB with BPaL was cost-saving for patients and cost-effective for the health system.Keywords
This publication has 12 references indexed in Scilit:
- A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2022
- Economic evaluation: a reader’s guide to studies of cost-effectivenessArchives of Physiotherapy, 2022
- Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant TuberculosisNew England Journal of Medicine, 2022
- Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic reviewPLOS ONE, 2022
- Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesBMJ Open, 2021
- Treatment of Highly Drug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2020
- Measuring income for catastrophic cost estimates: Limitations and policy implications of current approachesSocial Science & Medicine, 2018
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?Antimicrobial Agents and Chemotherapy, 2015
- A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant TuberculosisPharmacoEconomics, 2012